Published in final edited form as:

Bioorg Med Chem Lett. 2012 March 1; 22(5): 2125–2129. doi:10.1016/j.bmcl.2011.12.145.

Small molecule inhibitors of the HPV16-E6 interaction with caspase 8

Chung-Hsiang Yuan^a, Maria Filippova^a, Sandy S. Tungteakkhun^a, Penelope J. Duerksen-Hughes^a, and John L. Krstenansky^{b,a}

^aDepartment of Basic Sciences, Loma Linda University School of Medicine, 11085 Campus St., Loma Linda, CA 92354, USA

^bDepartment of Pharmaceutical Sciences, Loma Linda University School of Pharmacy, 11262 Campus St., Loma Linda, CA 92354, USA

Abstract

High-risk strains of human papillomaviruses (HPV) cause nearly all cases of cervical cancer as well as a growing number of head and neck cancers. The oncogenicity of these viruses can be attributed to the activities of their two primary oncoproteins, E6 and E7. The E6 protein has among its functions the ability to prevent apoptosis of infected cells through its binding to FADD and caspase 8. A small molecule library was screened for candidates that could inhibit E6 binding to FADD and caspase 8. Flavonols were found to possess this activity with the rank order of myricetin > morin > quercetin > kaempferol = galangin >> (apigenin, 7-hydroxyflavonol, rhamnetin, isorhamnetin, geraldol, datiscetin, fisetin, 6-hydroxyflavonol). Counter screening, where the ability of these chosen flavonols to inhibit caspase 8 binding to itself was assessed, demonstrated that myricetin, morin and quercetin inhibited GST-E6 and His-caspase 8 binding in a specific manner. The structure activity relationships suggested by these data are unique and do not match prior reports on flavonols in the literature for a variety of anticancer assays.

Keywords

cervical cancer; E6 protein; human papillomavirus type 16; HPV; flavonols; caspase 8; apoptosis

Human papillomavirus (HPVs) are small DNA viruses that infect human epithelial tissue such as that found in the genital tract, hands, and feet. There are more than 200 types of HPVs, which can be classified both on the basis of sequence homology, leading to assignments of species, and on the basis of whether infection with a particular type is likely to lead to cancer (high-risk vs. low-risk). Most, though not all, of the high-risk types are located within species 9 (reviewed in Munoz et al, 2006).¹ HPV types 16 (species 9) and 18 (species 7) are high-risk types, and are the causative agents of nearly all cases of human cervical cancer, between 20% and 30% of head and neck cancer cases, and some cases of other cancers.²⁻⁵ The HPV-encoded oncogenes E6 and E7 are responsible for cellular immortalization and transformation.⁶⁻⁸ While E7 is best known for the inactivation of Rb and thus for the immortalization of differentiated cells, E6 induces degradation of p53,

© 2012 Elsevier Ltd. All rights reserved.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

which serves as a critical tumor suppressor. In addition, E6 binds to and inactivates other cellular proteins involved in normal cellular functions.⁶⁻⁹

In our previous work, we found that E6 interacts with the extrinsic apoptosis pathway by binding to key signaling molecules such as TNF R1, FADD and caspase 8 and altering their functions, thus allowing HPV-infected cells to avoid clearance through apoptosis.¹⁰⁻¹³

Activation of the extrinsic apoptotic pathway normally begins with the binding of ligands such as TNF- α , FasL or TRAIL to their receptors, which then leads to recruitment of adaptor proteins such as FADD, TRADD and TRAF. A Death Inducing Signaling Complex (DISC) is then formed, which includes the initiator caspase, procaspase-8, bound to the adapter protein FADD. Procaspase 8 cleavage releases active cysteine-aspartic proteases, which then enable caspase 8 to cleave and activate effector caspases such as caspase 3 and 7 and to initiate apoptosis. If the HPV E6 oncoprotein is expressed in the cell, however, this sequence cannot occur. E6 binds to FADD and procaspase-8 and blocks the interaction between the two cellular proteins; this binding also increases the degradation of FADD and procaspase-8. Both events prevent the successful completion of apoptosis, and cells become resistant to cell death induced by TNF-, Fas-, and TRAIL.¹¹⁻¹³

Although two vaccines designed to prevent cervical cancer are now available,¹⁴⁻¹⁶ the development of effective therapeutic drugs directed against HPV infection and disease remains an urgent need. Because the vaccine is prophylactic rather than therapeutic, it will bring no benefit to women and men who are already infected. In fact, it will not have a significant effect on human health for decades, as most women become infected in their late teens/early twenties, while cancer appears in their late forties/early fifties. Furthermore, the vaccine targets only two of the high-risk strains (16 and 18), which together account for 70-75% of the cases, leaving 25-30% of the high-risk infections unaffected by an individual's vaccination status. Finally, the high cost and multiple boosters needed (three shots total) make it unlikely that this vaccine will become readily available in the developing world in the near future. For these reasons, the development of novel and effective therapeutic interventions for established cases of cervical cancer remains an urgent need.

Small molecule approaches have been used to inhibit important signal transduction pathways that are involved in breast, colon, pancreatic and lung cancer formation.^{17,18} However, such small molecule-based therapeutic agents have not yet been fully developed for HPV-mediated cancers. Our current knowledge of the molecular mechanisms by which HPV 16 E6 prevents apoptosis through the extrinsic pathway⁸⁻¹² has now allowed us to propose a novel approach for using small molecules to inhibit the binding between E6 and the key players of extrinsic apoptosis, FADD and procaspase 8. If this binding can be prevented, cells should be re-sensitized to apoptotic mediators such as TRAIL, and TRAIL-based therapy can then be successfully used to initiate apoptosis of E6-expressing tumor cells. In this paper we report on our results from screening a small molecule library for molecules that can prevent E6/FADD and E6/caspase 8 binding.

In this study, we used AlphaScreenTM technology (Perkin Elmer) to search for molecules capable of inhibiting E6/FADD and E6/caspase 8 binding. Secondary screening allowed us to eliminate a number of molecules from consideration, and suggested two classes of chemicals for further analysis. The best candidate was the flavonol, myricetin, which served as a potent inhibitor of E6/caspase 8 binding and helped to define the structure-activity relationship (SAR) of the ligands.

The construction of the pGEX-E6 and pTriEx-Caspase-8 DED plasmids has been reported.⁸ Expression and purification of GST-E6, His-FADD and His-Caspase-8 DED were carried out as previously described.^{8,19} GST-tagged and His-tagged proteins were diluted in GST

dilution buffer (PBS pH 8.0, 5% glycerol, 2 mM DTT) and His dilution buffer (20 mM Hepes pH 7.4, 150 mM NaCl, 2 mM KCl, 5% glycerol, 2 mM DTT). Protein concentration was measured using Coomassie Plus – The Better Bradford Assay Reagent (Thermo Scientific). The purity of the isolated proteins was estimated following separation by SDS-PAGE and Coomassie staining (Figure 1).

We began by using AlphaScreen™ technology to screen a 949 member small-molecule library from TimTec, LLC (Newark, DE) designed for similarity to kinase inhibitors. Members of the library were present at 10 μ M in DMSO. Briefly, GST-E6 and His-FADD proteins were purified from *E.coli* lysates after induction of protein expression by IPTG (Figure 1). 5 μ l (1 ng) of GST-E6 and 5 μ l (338 ng) of His-FADD were included in each reaction mixture with 5 μ l blocking buffer (0.5 mg BSA, 0.5% Tween 20 in PBS) in the absence or presence of 10 μ M of each test chemical. After a one-hour incubation of the mixture at room temperature, 5 μ l donor beads and 5 μ l acceptor beads (Perkin-Elmer) were added to each well according to the manufacturer's protocol. The mixture was incubated in the dark at room temperature overnight, and the emitted signal was detected using the Envision Multilabel plate reader (Perkin-Elmer). In the presence of test chemicals, the binding affinity was calculated as a percentage of the binding in the presence of carrier only (DMSO). Of the 949 chemicals initially screened, 108 chemicals demonstrated some ability to interfere with E6 binding (11.4% of the original set of chemicals). These chemicals were then re-tested in triplicate to confirm activity, and 61 of the 108 showed some inhibitory activity (6.4% of the initial 949 chemicals). The compounds that demonstrated a high level of activity (inhibition of 90% and higher) were tested again in triplicate at 1:10 and 1:100 dilutions (1 μ m and 0.1 μ m). Finally, those compounds that appeared to show a dose response relationship were retested at 1:50 and 1:500 dilutions in triplicate.

To analyze this screening data, we began with a SD file of the structures and the corresponding well layout provided by TimTec, LLC and imported it into an initial ChemFinder 11.0 database. The database was then exported into a ChemOffice for Excel spreadsheet. The structures were reviewed, and from these structures, a series of physical properties was calculated using the functions available in ChemOffice for Excel. These properties were: 1. cLogP: calculated log octanol/water partition coefficient; 2. number of hydrogen bond donor atoms; 3. number of hydrogen bond acceptor atoms; 4. number of rotating bonds; 5. polar surface area; 6. molar refractivity; 7. number of heavy atoms.

From these data, another column assessed these parameters and the compounds were judged as passing or failing the Lipinski Rule of Five.²⁰ The structures were also assessed visually for possible reactivity with thiol groups (e.g., Michael acceptors), as HPVE6 has 6 surface Cys thiol residues. Compounds that failed the Lipinski Rule of Five, were not "lead-like"²¹ ($100 < \text{MW} < 350$ & $1 < \text{clogP} < 3$) or were deemed potentially thiol-reactive were removed from consideration. After testing and data analysis we were left with 19 compounds from several different structural classes out of the original 949 compounds in the library.

Among the most potent of the 19 were a flavonol, kaempferol, and a flavone, chrysin 7-methyl ether. Notably, flavone and apigenin were in the original library and did not exhibit sufficient potency for selection. These data indicate that this class of compounds exhibits clear SAR at this binding site. Additionally, the literature contained several descriptions of this class of compounds having potential antitumor activity.²²⁻²⁶

We had shown previously that the E6 binding motifs on FADD and procaspase 8 proteins have a similar structure, and that the E6 binding to FADD and to procaspase 8 can be blocked by the same blocking peptide in both *in vivo* and *in vitro* assays.¹⁹ Consistent with these findings, we were able to verify that kaempferol could indeed inhibit both the His-

FADD and His-caspase 8 interaction with GST-E6 in a dose-dependent manner. Therefore, later analyses were carried out using His-caspase 8 DED rather than His-FADD. Two advantages for the change were: 1) the His-caspase 8 DED protein proved easier to consistently purify than His-FADD as a properly folded protein, therefore giving us greater consistency in our assay results, and; 2) using this assay allowed us to perform analogous counter-screening to demonstrate specificity, by asking whether candidate molecules did or did not inhibit the binding between His-caspase 8 and GST-caspase 8.

To follow up on the flavone/flavonol hits, nineteen flavones and flavonol compounds representing systematic substitution of the ring system were selected and purchased, and then tested for inhibition of the E6/caspase 8 interaction (Table 1). We sought to determine the SAR for these ligands with regards to their binding to E6, and also asked whether the SAR corresponded to the prior literature or was unique.

AlphaScreen™ technology (Perkin Elmer) was used to detect the interaction between GST-E6 and His-caspase 8 using the same methodology and incubation times described above. The binding reaction was performed in a 384-well plate format in a total volume of 25 μ l per well. Each well contained 5 μ l GST-E6 protein (4.37 ng), 5 μ l His-caspase 8 protein (50 ng), 5 μ l blocking buffer (0.5 mg BSA, 0.5% Tween 20 in PBS), 5 μ l chemical compounds at different concentrations diluted in PBS, and 5 μ l of the acceptor and donor beads solution.

The structural characteristics of tested flavones are presented in Table 1. Each of these compounds was tested at 4 different concentrations, from 20 nM to 20 μ M, and the results demonstrated that 6 of them, including kaempferol, inhibited the interaction between E6 and caspase 8. These data of relative potency gave the following ranking: **1** > **2** > **3** > **4** = **5** >> (**6** to **19**). The structure activity relationship (SAR) that these data suggest are that the 3,5,7-OH groups are all important:

and that in the prime ring hydroxyl groups affect potency:

Additionally, we determined the IC₅₀ for **1-5** and **13** (Figure 2). For kaempferol and quercetin the IC₅₀ was greater than 20 μ M, while for morin, 50% inhibition was achieved at 4 μ M. The compound with the lowest IC₅₀ concentration was myricetin with an IC₅₀ of approximately 850 nM.

The mammalian two-hybrid system has previously been used to show that caspase 8 binds to itself.²³ For this reason, we were able to use this system to determine the specificity of the inhibitors, as compounds that inhibited the caspase 8/caspase 8 binding were likely to either interact with caspase 8 rather than E6, or to influence the assay itself in a non-specific manner. Therefore, to determine whether the observed inhibitions were indeed specific, or whether they might instead reflect some nonspecific mechanism related to the assay method, candidate compounds were tested for their ability to inhibit binding between GST-caspase 8 and His-caspase 8. As shown in Figure 3, we found that myricetin, morin and 6-hydroxy flavonol exhibited no inhibition of caspase 8/caspase binding over a range of concentrations.

The structure activity relationship we observe for the inhibition of HPV16 E6 binding to caspase 8 is distinctly different from prior reports of flavones in a variety of *in vivo* and *in vitro* anticancer assays.²⁴⁻²⁸ The reducing environment of the assays, the distinct SAR, and the specificity experiments all indicate that this is a real inhibition by the flavonols and not a non-specific artifact from flavonol oxidation products. Therefore, these results represent the first report of the potential of flavonols for the prevention or reversal of HPV-induced apoptotic blockade. Preliminary *in vivo* studies (data not reported here) indicate a weak ability for myricetin to suppress TRAIL induced tumor growth. Poor cellular penetration is likely the reason for the result due to the highly polar nature of the compound. Since the polar groups are an important feature of the SAR, optimization of this series of compounds would be difficult without resorting to a prodrug approach, further complicating the optimization process. Therefore, we are also engaged in additional screening efforts with libraries containing more 'lead-like' members that will enable optimization.²⁹

Acknowledgments

This work was supported in part by grant CA095461 from the National Institutes of Health (PDH).

Abbreviation

HPV	Human Papillomavirus
TNF R1	Tumor necrosis factor receptor 1
FADD	Fas-Associated protein with death domain
TRAIL	TNF-related apoptosis-inducing ligand protein
TRADD	Tumor necrosis factor receptor type 1-associated death domain protein
TRAF	TNF receptor associated factors
DISC	Death-inducing signaling complex
SAR	Structure-activity relationship
GST	Glutathione S-transferase
DMSO	Dimethyl sulfoxide

References and notes

- Munoz N, Castellsague X, Berrington de Gonzalez A, Gissmann L. Chapter 1: HPV in the etiology of human cancer. *Vaccine*. 2006; 24:S3/1–S3/10.
- Garland SM, Faulkner-Jones BE, Fortune DW, Quinn MA. *Med. J. Aust.* 1992; 156:204. [PubMed: 1312213]
- Kreimer AR, Clifford GM, Boyle P, Franceschi S. *Cancer Epidemiol. Biomarkers Prev.* 2005; 14:467.
- Alam M, Caldwell JB, Eliezri YD. *J. Am. Acad. Dermatol.* 2003; 48:385. [PubMed: 12637918]
- Ragin CCR, Taioli E. *Int. J. Cancer.* 2007; 121:1813. [PubMed: 17546592]
- Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B, Tommasino M. *Virus Genes.* 2010; 40:1. [PubMed: 19838783]
- Moody CA, Laimins LA. *Nat. Rev. Cancer.* 2010; 10:550. [PubMed: 20592731]
- Tungteakkhun SS, Filippova M, Neidigh JW, Fodor N, Duerksen-Hughes PJ. *J. Virology.* 2008; 82:9600. [PubMed: 18632871]
- Tungteakkhun SS, Duerksen-Hughes PJ. *Arch. Virol.* 2008; 153:397. [PubMed: 18172569]
- Garnett TO, Filippova M, Duerksen-Hughes PJ. *Cell Death Differ.* 2006; 13:1915. [PubMed: 16528386]

11. Filippova M, Johnson MM, Bautista M, Filippov V, Fodor N, Tungteakkhun SS, Williams K, Duerksen-Hughes PJ. *J. Virol.* 2007; 81:4116. [PubMed: 17267478]
12. Filippova M, Parkhurst L, Duerksen-Hughes PJ. *J. Biol. Chem.* 2004; 279:25729. [PubMed: 15073179]
13. Filippova M, Song H, Connolly JL, Dermody TS, Duerksen-Hughes PJ. *J. Biol. Chem.* 2002; 277:21730. [PubMed: 11934887]
14. Romanowski B, de Borja PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, Aoki F, Ramjattan B, Shier RM, Somani R, Barbier S, Blatter MM, Chambers C, Ferris D, Gall SA, Guerra FA, Harper DM, Hedrick JA, Henry DC, Korn AP, Kroll R, Moscicki AB, Rosenfeld WD, Sullivan BJ, Thoming CS, Tying SK, Wheeler CM, Dubin G, Schuind A, Zahaf T, Greenacre M, Sgriobhadair A. *Lancet.* 2009; 374:1975. [PubMed: 19962185]
15. Garland SM, Smith JS. *Drugs.* 2010; 70:1079. [PubMed: 20518577]
16. Scarinci IC, Garcia FA, Kobetz E, Partridge EE, Brandt HM, Bell MC, Dignan M, Ma GX, Daye JL, Castle PE. *Cancer.* 2010; 116:2531. [PubMed: 20310056]
17. Yi C, Maksimoskab J, Marmorsteinb R, Kissil JL. *Biochemical Pharmacology.* 2010; 80:683. [PubMed: 20302846]
18. D'Abramo CM, Archambault J. *The Open Virology J.* 2011; 5:80–95.
19. Tungteakkhun SS, Filippova M, Fodor N, Duerksen-Hughes PJ. *J. Virology.* 2010; 84:1453. [PubMed: 19906919]
20. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. *Adv. Drug Del. Rev.* 2001; 46:3.
21. Curtin F, Schulz P. *Biol Psychiatry.* 1998; 44(8):775–7. [PubMed: 9798082]
22. Teague SJ, Davis AM, Leeson PD, Oprea T. *Angew. Chem., Int. Ed.* 1999; 38:3743.
23. Filippova M, Johnson MM, Bautista M, Filippov V, Fodor N, Tungteakkhun SS, Williams K, Duerksen-Hughes PJ. *J. Virology.* 2007; 81(8):4116–29. [PubMed: 17267478]
24. Ren W, Qiao Z, Wang H, Zhu L, Zhang L. *Med. Res. Rev.* 2003; 23:519. [PubMed: 12710022]
25. Lee HG, Yu KA, Oh WK, Baeg TW, Oh HC, Ahn JS, Jang WC, Kim JW, Lim JS, Choe YK, Yoon DY. *J. Ethnopharmacology.* 2005; 98:339.
26. Ramanouskaya TV, Smolnykova VV, Grinev VV. *Anticancer Drugs.* 2009; 20:573. [PubMed: 19491655]
27. Ichimatsu D, Nomura M, Nakamura S, Moritani S, Yokogawa K, Kobayashi S, Nishioka T, Miyamoto K. *Mol. Carcinog.* 2007; 46:436. [PubMed: 17219438]
28. Moridani MY, Galati G, O'Brien PJ. *Chem. Biol. Interact.* 2002; 139:251. [PubMed: 11879815]
29. Hann MM, Oprea TI. *Curr. Opin. Chem. Biol.* 2004; 8:255. [PubMed: 15183323]

Figure 1. Purity of isolated proteins

Purified proteins (10 μ g) were separated by SDS-PAGE. The gel was then stained using the Coomassie reagent. Lane 1: GST-E6, Lane 2: GST-caspase 8, Lane 3: His-caspase 8

Figure 2. IC₅₀ determination of selected compounds

The binding between GST-E6 and His-caspase 8 DED was used to determine the IC₅₀ of each test chemical. 4.37 ng of GST-E6 and 50 ng His-caspase 8 were mixed in each well and the indicated concentrations of the test chemicals were applied. Binding in the presence of DMSO only was set at 100%. P-values were 0.05 when morin was compared to 6-hydroxy flavonol, galangin, kaempferol, and quercetin at 40 μ M and 13 μ M, and to 6-hydroxy flavonol, galangin, kaempferol, quercetin, and myricetin at 4 μ M and 1.3 μ M. P-values were 0.05 when myricetin was compared to 6-hydroxy flavonol, galangin, kaempferol, quercetin, and morin at 40 μ M, 13 μ M, 4 μ M and 1.3 μ M. The p-values were obtained by multiple comparisons using the Bonferroni correction.²¹

Figure 3. Specificity of the inhibition of E6/caspase 8 binding

The ability of myricetin, morin, and 6-hydroxy flavonol to inhibit binding between His-caspase 8 and either GST-E6 or GST-caspase 8 was assessed using the bead-based binding assay, as described in the legend for Figure 2. Where indicated, 13.5 ng GST-caspase 8 was added to each well. P-values were 0.001 when myricetin and morin were compared to 6-hydroxy flavonol only in GST-E6/His-caspase 8 group. The p-values were obtained by multiple comparisons using the Bonferroni correction.

Table 1

Structures of the flavones and 3-flavonols tested for their ability to inhibit the interaction between HPV E6 and caspase 8. Position numbers are given on the structure as the superscript.

Compound	3	5	6	7	8	2'	3'	4'	5'	6'
myricetin (1)	OH	OH	H	OH	H	H	OH	OH	OH	H
morin (2)	OH	OH	H	OH	H	OH	H	OH	H	H
quercetin (3)	OH	OH	H	OH	H	H	OH	OH	H	H
kaempferol (4)	OH	OH	H	OH	H	H	H	OH	H	H
galangin (5)	OH	OH	H	OH	H	H	H	H	H	H
apigenin (6)	H	OH	H	OH	H	H	H	OH	H	H
7-hydroxyflavonol (7)	OH	H	H	OH	H	H	H	H	H	H
rhamnetin (8)	OH	OH	H	OMe	H	H	OH	OH	H	H
isorhamnetin (9)	OH	OH	H	OH	H	H	OMe	OH	H	H
geraldol (10)	OH	H	H	OH	H	H	OMe	OH	H	H
datiscetin (11)	OH	OH	H	OH	H	OH	H	H	H	H
fisetin (12)	OH	H	H	OH	H	H	OH	OH	H	H
6-hydroxyflavonol (13)	OH	H	OH	H	H	H	H	H	H	H
7-methoxyflavonol (14)	OH	H	H	OMe	H	H	H	H	H	H
(15)	OH	H	CH ₂ COOH	H	Cl	H	H	H	H	H
(16)	OH	H	CH ₂ COOH	H	Cl	H	H	Cl	H	H
(17)	OH	H	CH ₂ COOH	H	Cl	H	H	CH(Me) ₂	H	H
flavonol (18)	OH	H	H	H	H	H	H	H	H	H
flavone (19)	H	H	H	H	H	H	H	H	H	H